Drug intelligence / Profile preview

BR1018C

Development stage: Phase 3
Lead developer: Boryung
Modality: Small Molecules
Administration: Oral

Overview

BR1018C is an investigational small molecule drug developed by Boryung Corp. It is being studied as part of a combination therapy (notably with BR1018B) for the treatment of essential hypertension and primary hypercholesterolemia. The drug is currently in Phase 3 clinical trials, where its efficacy and safety are being evaluated in patients with both high blood pressure and elevated cholesterol levels. The precise mechanism of action, molecular target(s), and detailed pharmacological profile have not been publicly disclosed as of June 2025[1][2][3][7].

Other names: BR1018CBR-1018CBR 1018C

Beyond the preview

Go deeper on BR1018C.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BR1018C.

Explore the full profile